Abstract
1-O-Hexadecyl-2-O-acetyl-sn-glycerol-3-phosphocholine (platelet-activating factor, PAF) is known to stimulate platelet aggregation and serotonin release in concentrations ranging from 10−10–10−5 M. Since a variety of synthetic PAF analogues are potent antineoplastic agents in vitro and in vivo, it was the aim of this study to examine the PAF-like activity of 15 analogues, including 1-O-actadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-18-OCH3) and a thioether analogue. In platelet-rich plasma from human blood, platelet aggregation and serotonin release were studied to compare the effects on PAF and the analogues. Platelet function was controlled by testing their response to adenosine diphosphate, arachidonic acid, collagen and epinephrine. Our results show that only PAF was able to induce platelet aggregation and serotonin release in concentrations from 10−9 to 10−5 M, whereas all the tested analogues up to a concentration of 10−3 M failed to induce these effects.
Similar content being viewed by others
Abbreviations
- PAF:
-
platelet activating factor
- PPP:
-
platelet-poor plasma
- PRP:
-
platelet-rich plasma
- BSA:
-
bovine serum albumin
- ET-18-OCH:
-
I-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
- BM 41.440:
-
1-hexadecylmercapto-2-methoxymethyl-rac-glycero-3-phosphocholine
References
Marcus, A.J., Safier, L.B., Ullman, H.L., Wong, K.T.H., Broekman, M.J., Weksler, B.B., and Kaplan K.L. (1981)Blood 58, 1027–1031.
McManus, M.L., Hanahan, D.J., and Pinkard, R.N. (1981)J. Clin. Invest. 67, 903–906.
Chesney, C.M., Pifer, D.D., and Muichead, E.E. (1982)Blood 59, 582–585
Benveniste, J., Henson, P.M., and Cochrane, L.G. (1972)J. Exp. Med. 136, 1356–1377.
Demopulos, C.A., Pinckard, R.N., and Hanahan, D.J. (1979)J. Biol. Chem. 254, 9355–9358.
Benveniste, J., Roubin, R., Chignard, M., Jourinmarche, E., and Le Couedic, J.P. (1982)Agents Actions 12, 711–713.
Benveniste, J., Tence, M., Varenne, P., Bidault, J., Boullet, C., and Polonsky, J. (1979)C.R. Acad. Sci. Ser. D 289, 1037–1040.
Lefer, M.A., Müller, H.F., and Smith, B. (1983)Br. J. Pharmacol. 83, 125–130.
Heffner, J., Shoemaker, S.A., Canham, E.M., and Patel, M. (1983)J. Clin. Invest. 71, 351–357.
Ambler, J., and Wallis, R.B. (1983)Thromb. Res. 31, 577–589.
Vargaftig, B.B., Fouque, F., Benveniste, J., and Odiot, J. (1982)Thromb. Res. 28, 557–573.
Valone, F.H., and Johnson, B. (1985)J. Immunol. 134, 1120–1124.
Eibl, H. (1984)Angew. Chem. 23, 257–271.
Eibl, H. (1981)Liposomes, from Physical Structure to Therapeutic Application (Knight, C.G., ed.) pp. 19–33, Elsevier, Amsterdam.
Holmsen, H., and Dangermaier, C.A. (1981)J. Biol. Chem. 256, 10449–10452.
Wykle, R.L., Miller, C.H., Lewis, J.C., Jeffrey, D.S., Smith, J.A., Surles, J.R., Piantadosi, C., and Flaherty, J.T. (1981)Biochem. Biophys. Res. Commun. 100, 1651–1658.
Tence, M., Coeffier, E., Keraly, C.L., and Broquet, L. (1983)Platelet-Activating Factor and Structural Related Ether-Lipids (Benveniste, J., and Arnoux, B., ed.) pp. 41–48, Elsevier Science Publishers, Amsterdam.
Author information
Authors and Affiliations
About this article
Cite this article
Söling, U., Eibl, H., Nagel, G.A. et al. Effect of synthetic phospholipids on platelet aggregation and serotonin release. Lipids 22, 868–870 (1987). https://doi.org/10.1007/BF02535546
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02535546